UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34703 Alimera Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 20-0028718 (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34703 Alimera Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 20-0028718 (State or other jurisdi ...

Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2022 Earnings Conference Call March 31, 2023 9:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President & CEO Russell Skibsted - SVP and CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Yi Chen - H.C. Wainwright & Co., LLC Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences 2022 Financial Results Conference Call. At this time, all participants are in a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34703 Alimera Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 20-0028718 (State or other jurisdiction ...

Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2022 Results Conference Call November 14, 2022 9:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President & Chief Executive Officer Phil Jones - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Laura Sorel - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences Third Quarter 2022 Financial Results and Corporat ...

Alimera Sciences, Inc. (NASDAQ:ALIM) Q2 2022 Earnings Conference Call July 27, 2022 9:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President & Chief Executive Officer Phil Jones - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Yi Chen - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Science Second Quarter 2022 Financial Results and Corporate Update Conference Ca ...

Financial Data and Key Metrics Changes - Consolidated revenue for Q1 2022 was $11.9 million, up 6% compared to Q1 2021 [7][20] - U.S. net revenue increased by 23% to $6.9 million from $5.6 million in the same period last year [20] - Adjusted EBITDA loss was $3.1 million in Q1 2022, compared to a loss of $1.3 million in Q1 2021 [24] - Net loss for Q1 2022 was $6 million, compared to a net loss of $3.6 million in Q1 2021 [24] - Basic and diluted net loss per share for Q1 2022 was $0.85, compared to $0.63 in Q1 2021 [25] Business Line Data and Key Metrics Changes - U.S. end user demand grew 25% to 918 units in Q1 2022 compared to 737 units in Q1 2021 [7][20] - International segment sales decreased by 11% year-over-year to $5 million due to COVID-19 impacts [22] - End user demand in international distributor markets was up 9% in Q1 2022 versus Q1 2021 [15][22] Market Data and Key Metrics Changes - End user demand in the U.S. was up 30% year-to-date through April 2022 compared to the same period in 2021 [9] - Demand in Portugal was up 35% in Q1 2022 over the prior year [17] - The U.K. returned to growth at the end of April 2022 in a year-over-year comparison [17] Company Strategy and Development Direction - The company is focusing on increasing engagement with retina specialists and has restarted a direct-to-patient campaign to support growth [11][13] - Anticipated launches for non-infectious posterior uveitis in Portugal and France are expected to contribute to growth [27] - The company is controlling spending in European markets to align with current revenue levels [18][26] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing recovery from the pandemic across most markets and expects strong performance to continue throughout the year [7][27] - The company aims to achieve adjusted EBITDA break-even or better in future quarters to mitigate cash burn [26] - Management expressed confidence in returning to pre-COVID run rates by mid to late Q3 2022 [40] Other Important Information - The company is enrolling patients in the NEW DAY study, which is over 50% enrolled [19] - The company has received orders for approximately 2,300 units valued at over $6 million for 2022 from international distributors [15][22] Q&A Session Summary Question: How is the PALADIN data influencing physician habits post-pandemic? - Management indicated a shift in treatment approaches for diabetic macular edema is occurring, with increased recognition of the need for anti-inflammatory treatments alongside anti-VEGF therapies [31][32] Question: What is the impact of the FDA's new requirements on commercialization? - Management does not anticipate significant impacts on ILUVIEN's commercialization but is monitoring the situation closely [42] Question: What were the non-performing items in spending? - Management mentioned postponing certain investments in advisory boards and additional personnel until patient flow justifies those expenses [46][47] Question: Is the company still on track for 15% year-over-year growth? - Management confirmed they feel good about achieving that growth, despite some supply chain issues [48][49] Question: How is the sales team performing? - Management expressed satisfaction with the U.S. sales team performance, noting they are close to hitting targets consistently [51]